Engineered chimeric antimicrobial agents against gram-positive bacteria

A chimeric bacteriophage lysin comprising a catalytic domain of a first phage lysin and a binding domain of a second phage lysin, wherein the chimeric lysin has killing activity against a plurality of Staphylococcus species, wherein the lysin comprises an amino acid sequence set forth in:

• a) SEQ ID NO:
• 11, or a variant thereof wherein said variant is capable of killing staphylococci;
• b) amino acids 1-165 and 170-338 set forth in SEQ ID NO:
• 9, or a variant thereof wherein said variant is capable of killing staphylococci;
• c) amino acids 1-145 and 150-242 set forth in SEQ ID NO:
• 13, or a variant thereof wherein said variant is capable of killing staphylococci;
• d) amino acids 1-165 and 170-262 set forth in SEQ ID NO:
• 15, or a variant thereof wherein said variant is capable of killing staphylococci.